outbreak
merscov
saudi
arabia
sarscov
china
introduc
two
highli
pathogen
coronavirus
human
popul
soon
initi
identif
merscov
epidem
spread
mani
countri
outsid
arabian
peninsula
infect
travel
notabl
south
korea
februari
confirm
case
mer
associ
death
report
estim
fatal
rate
high
like
sar
infect
asymptomat
mer
case
also
report
suggest
diseas
develop
like
depend
upon
health
statu
possibl
genet
infect
individu
till
today
still
ongo
report
human
merscov
infect
affect
region
mani
link
direct
contact
dromedari
believ
major
reservoir
host
merscov
immedi
sourc
human
infect
dromedari
critic
livestock
vital
mean
transport
affect
region
infect
persist
merscov
anim
repres
longterm
global
health
threat
highlight
urgent
need
effect
prophylact
therapeut
intervent
like
sarscov
protein
merscov
play
critic
role
mediat
viral
entri
induc
protect
antibodi
respons
infect
individu
experiment
anim
protein
typic
type
membran
glycoprotein
consist
globular
domain
ntermin
region
follow
membraneproxim
domain
transmembran
domain
determin
host
rang
cellular
tropism
locat
receptorbind
domain
rbd
within
domain
mediat
membran
fusion
identifi
within
domain
merscov
enter
host
airway
epitheli
cell
interact
rbd
cellular
receptor
dipeptidyl
peptidas
fusion
either
plasma
endosom
membran
other
recent
character
crystal
structur
merscov
rbd
bound
extracellular
domain
human
studi
show
merscov
rbd
consist
core
receptor
bind
subdomain
receptor
bind
subdomain
directli
interact
blade
propel
intrins
hydrolas
domain
suggest
agent
capabl
disrupt
bind
interact
could
serv
candid
block
entri
merscov
target
cell
inde
polyclon
monoclon
antibodi
direct
rbd
shown
inhibit
merscov
infect
primari
human
bronchial
epitheli
cell
cell
particular
other
isol
close
twenti
neutral
monoclon
antibodi
target
rbd
merscov
protein
interfer
bind
cellular
receptor
crystal
structur
analys
neutral
antibodi
reveal
spatial
overlap
competit
bind
neutral
antibodi
remain
promis
option
prevent
treat
merscov
infect
cost
associ
rel
high
vaccin
candid
abl
induc
type
neutral
antibodi
target
rbd
would
highli
prefer
therefor
protein
rbd
critic
compon
variou
vaccin
formul
investig
aim
induc
type
neutral
antibodi
mention
report
vaccin
candid
direct
rbd
protein
shown
elicit
neutral
activ
merscov
vitro
protect
activ
variou
anim
model
howev
candid
hamper
limit
immunogen
often
requir
multipl
round
immun
induc
detect
neutral
antibodi
protect
viral
challeng
current
studi
aim
develop
vaccin
candid
capabl
induc
potent
protect
immun
merscov
singl
immun
end
sought
gener
recombin
rare
serotyp
chimpanze
adenoviru
express
rbdcontain
fulllength
merscov
protein
immunogen
protect
activ
systemat
evalu
lethal
challeng
mouseadapt
merscov
merscovma
previous
develop
human
knockin
mous
model
chimpanze
adenovirus
chose
vector
due
low
preexist
immun
overal
safeti
profil
seroposit
human
compar
human
adenoviru
serotyp
seropreval
recombin
vaccin
base
rare
serotyp
chimpanze
adenovir
vector
recent
engin
express
variou
antigen
demonstr
impress
safeti
immunogen
profil
clinic
studi
report
singl
intranas
immun
induc
robust
sustain
neutral
antibodi
cell
respons
balbc
mice
superior
commonli
use
intramuscular
vaccin
human
knockin
mous
model
induc
immun
respons
complet
protect
lethal
challeng
mouseadapt
merscov
merscovma
furthermor
passiv
transfer
immun
sera
mice
also
provid
surviv
advantag
lethal
merscovma
challeng
seri
serum
absorpt
monoclon
antibodi
isol
immun
anim
show
potent
broad
neutral
activ
immun
anim
larg
attribut
antibodi
target
rbd
protein
result
show
induc
desir
favour
antibodi
respons
capabl
disrupt
interact
rbd
receptor
therefor
repres
promis
candid
develop
merscov
infect
dromedari
human
cell
virus
anim
hek
hek
cell
repres
two
differ
subclon
parent
cell
line
origin
human
embryon
kidney
hek
cell
cell
hepatocyt
carcinoma
cell
line
origin
deriv
liver
tumor
cell
line
purchas
atcc
maintain
complet
dulbecco
modifi
eagl
medium
dmem
gibco
supplement
foetal
bovin
serum
fb
gibco
incub
merscov
protein
gene
sequenc
genbank
number
optim
express
adenovir
vector
chemic
synthes
genscript
china
mouseadapt
strain
merscov
gener
previous
describ
use
univers
iowa
sixweek
old
femal
balbc
mice
purchas
beij
vital
river
laboratori
anim
technolog
co
ltd
licens
charl
river
hous
specif
pathogen
free
spf
mous
facil
spf
human
knockin
hdppki
mice
gener
previous
describ
univers
iowa
mice
lightli
anesthet
use
isofluran
intranas
infect
lethal
dose
pfu
merscovma
dmem
work
merscovma
conduct
biosafeti
level
bsl
anim
laboratori
univers
iowa
ethic
statement
experi
carri
strict
complianc
guid
care
use
laboratori
anim
peopl
republ
china
approv
committe
ethic
anim
experi
tsinghua
univers
anim
neutral
experi
merscovma
perform
bsl
facil
univers
iowa
biosafeti
per
institut
anim
care
use
committe
iacuc
guidelin
institut
biosafeti
committe
approv
experi
involv
merscovma
construct
recombin
adenovir
vector
merscov
codonoptim
gene
merss
clone
pshuttlemerss
digest
iceui
piscei
releas
merss
fragment
cmv
promot
extend
fragment
contain
merss
fragment
separ
agaros
gel
insert
iceuipiscei
site
gener
rescu
amplif
purif
recombin
chimpanze
adenoviru
type
use
studi
replic
defici
chimpanze
adenoviru
due
delet
domain
viral
genom
defect
form
could
rescu
protein
express
suppli
hek
cell
line
specif
hek
cell
seed
plate
day
transfect
cell
cultur
overnight
confluenc
dmem
fb
solut
linear
paci
transfect
hek
cell
use
lipofectamin
accord
manufactur
instruct
life
technolog
carlsbad
ca
rescu
replic
defici
recombin
chimpanze
adenoviru
viru
amplifi
hek
cell
stabli
integr
express
gene
virus
purifi
round
cscl
gradient
ultracentrifug
follow
desalt
biogel
dg
media
biorad
usa
similarli
empti
gener
without
target
gene
insert
vector
purifi
describ
detect
merscov
express
hek
cell
infect
viru
use
detect
merscov
express
western
blot
surfac
stain
use
flow
cytometri
specif
hek
cell
seed
plate
one
day
transfect
grown
log
phase
infect
either
viru
vari
dose
vpswell
twentyfour
hour
postinfect
cell
harvest
lyse
ripa
buffer
contain
cocktail
proteas
inhibitor
western
blot
detect
express
merscov
spike
protein
run
antimerscov
polyclon
antibodi
sino
biolog
china
immunoblot
includ
control
protein
extract
hek
cell
infect
virus
use
neg
control
cell
surfac
analysi
previous
isol
three
monoclon
antibodi
specif
merscov
use
stain
viru
infect
cell
one
hour
later
cell
wash
stain
secondari
antibodi
antihuman
iggp
santa
cruz
biotechnolog
usa
one
hour
later
cell
wash
analys
bd
calibur
fac
cytomet
bd
usa
antibodi
specif
human
immunodefici
viru
type
use
neg
control
immun
sampl
collect
total
two
batch
anim
immun
batch
mice
randomli
distribut
twelv
group
n
per
group
vaccin
vari
dose
recombin
vaccin
candid
control
virus
control
pb
via
either
intramuscular
im
intranas
rout
describ
figur
mous
sera
harvest
everi
week
week
batch
ii
mice
randomli
distribut
four
group
n
per
group
vaccin
im
rout
describ
figur
mous
sera
harvest
everi
week
week
three
mice
group
sacrif
week
immun
spleen
harvest
cytokin
releas
analysi
sera
heatinactiv
min
analys
merscov
specif
antibodi
antibodi
subclass
cell
respons
immun
anim
merscov
specif
igg
iga
antibodi
respons
detect
elisa
briefli
serial
dilut
mous
sera
ad
microtit
plate
precoat
protein
produc
hek
cell
ngwell
plate
incub
h
wash
time
pbst
incub
either
horseradish
peroxidas
conjug
antimous
igg
promega
abcam
abcam
iga
abcam
h
sampl
wash
time
pbst
phosphat
buffer
salinetween
tmb
benzidin
ad
plate
reaction
stop
ad
absorb
read
nm
use
elisa
plate
reader
valu
calcul
base
bind
curv
drawn
graphpad
graphpad
softwar
inc
evalu
antigenspecif
tcell
respons
splenocyt
per
well
stimul
merscov
peptid
h
secret
cultur
supernat
analys
elisa
kit
dakew
china
epitop
map
competit
bind
antibodi
antibodi
first
label
biotin
antibodi
serial
dilut
threefold
biotinlabel
antibodi
ad
fix
concentr
mixtur
antibodi
appli
proteinco
plate
incub
h
thorough
wash
pbst
ngml
streptavidinhrp
sigma
usa
ad
incub
ambient
temperatur
min
develop
substrat
tmb
describ
pseudoviru
live
viru
neutral
assay
neutral
titr
immun
mous
sera
determin
use
previous
report
merscov
pseudoviru
live
viru
assay
pseudoviru
assay
sera
sampl
serial
dilut
cell
cultur
plate
merscov
pseudoviru
ad
incub
h
number
cell
ad
well
incub
h
neutral
result
measur
luciferas
activ
rel
light
unit
vigor
china
live
viru
assay
sera
sampl
collect
describ
serial
dilut
cell
cultur
plate
merscovmerscovma
ad
well
incub
h
ad
plate
precoat
vero
cell
incub
day
neutral
titr
determin
crystal
violet
stain
lung
viru
titr
determin
lung
viru
titr
mice
infect
merscovma
euthan
postchalleng
lung
remov
transcardi
perfus
pb
homogen
pb
viral
titr
determin
vero
cell
repres
plaqueform
unit
pfu
lung
cell
fix
formaldehyd
stain
crystal
violet
dpi
sequenc
analysi
statist
sequenc
align
perform
bioedit
bioedit
softwar
inc
phylogenet
analysi
gener
use
program
mega
mega
softwar
inc
halfmaxim
inhibitori
dilut
halfmaxim
effect
dilut
calcul
serum
use
graphpad
prism
softwar
graphpad
softwar
inc
monoclon
antibodi
estim
graphpad
data
express
mean
mean
standard
deviat
signific
differ
analys
use
student
ttest
statist
signific
surviv
studi
calcul
use
logrank
test
confid
interv
ci
result
graph
mean
sem
construct
recombin
chimpanze
adenoviru
vaccin
clone
fulllength
merscov
spike
gene
delet
region
genom
spike
gene
codonoptim
base
human
merscov
isol
control
cmv
promot
figur
recombin
viru
produc
hek
cell
purifi
cscl
gradient
ultracentrifug
quantifi
viral
particl
vp
measur
wavelength
absorb
nm
assess
spike
protein
express
perform
western
blot
analysi
hek
cell
lysat
infect
use
rabbit
polyclon
antim
antibodi
shown
figur
b
detect
dosedepend
express
spike
protein
two
promin
form
one
high
molecular
weight
mw
repres
fulllength
spike
glycoprotein
low
molecular
weight
mw
correspond
subunit
cleav
spike
glycoprotein
cell
surfac
stain
also
carri
confirm
protein
express
infect
hek
cell
use
antibodi
specif
rbd
merscov
previous
isol
group
figur
c
result
demonstr
success
robust
express
merscov
protein
surfac
within
infect
cell
next
studi
impact
dose
rout
vaccin
immunogen
balbc
mice
overal
scheme
group
design
immun
immunolog
character
outlin
figur
experi
conduct
two
consecut
batch
first
group
mice
follow
week
second
guid
result
obtain
first
batch
focus
week
immun
anim
batch
singl
immun
high
vp
medium
vp
low
vp
dose
administ
either
intramuscular
im
intranas
rout
sequenti
sera
sampl
collect
week
postvaccin
analys
bind
neutral
activ
pseudotyp
live
merscov
shown
figur
b
immun
group
except
develop
high
level
bind
antibodi
earli
weektwo
postimmun
antibodi
respons
continu
increas
persist
postimmun
wpi
figur
b
fig
high
bind
level
coincid
potent
broad
neutral
activ
merscov
pseudoviru
carri
wildtyp
natur
occur
mutant
envelop
figur
c
immun
sera
wildtyp
pseudovirus
reach
high
dilut
around
week
persist
similar
increas
higher
level
wpi
figur
c
fig
addit
immun
sera
demonstr
potent
broad
neutral
activ
major
mutant
pseudovirus
deriv
natur
occur
merscov
spike
sequenc
averag
immun
sera
im
week
respect
figur
fig
importantli
immun
sera
also
demonstr
potent
neutral
activ
live
merscov
consist
result
pseudoviru
assay
immun
sera
reach
averag
respect
vector
control
group
detect
neutral
activ
figur
e
f
furthermor
found
intranas
immun
induc
stronger
antibodi
respons
compar
intramuscular
rout
dose
group
fig
exampl
wpi
averag
lowdos
group
im
im
mediumdos
group
im
highdos
group
respect
practic
costeffect
reason
select
medium
dose
followup
character
batch
ii
batch
ii
balbc
mice
immun
mediumdos
vp
blank
vp
pb
via
im
rout
sequenti
sera
saliva
sampl
collect
week
postvaccin
analys
bind
neutral
activ
pseudotyp
merscov
shown
figur
g
anim
immun
im
rout
detect
iga
respons
saliva
peak
wpi
gradual
declin
ensu
period
anim
also
display
higher
level
sera
total
igg
level
compar
figur
h
earli
wpi
total
igg
detect
continu
rise
wpi
comparison
anim
either
sustain
lower
respons
significantli
delay
respons
particularli
wpi
figur
f
fig
analys
merscov
specif
cell
respons
measur
level
secret
splenocyt
stimul
peptid
wpi
anim
produc
significantli
higher
level
compar
figur
g
result
indic
singl
intranas
immun
induc
superior
antibodi
cellular
immun
respons
equival
intramuscular
immun
therefor
select
mediumdos
vp
intranas
immun
subsequ
evalu
protect
live
merscov
challeng
mous
model
next
evalu
protect
efficaci
vaccin
use
newli
develop
mous
model
fatal
merscov
infect
figur
n
specif
total
mice
receiv
vaccin
via
intranas
rout
receiv
blank
vector
neg
control
ten
wpi
anim
challeng
intranas
lethal
dose
plaqueform
unit
pfu
mouseadapt
merscovma
half
anim
group
monitor
daili
surviv
bodi
weight
chang
throughout
followup
half
sacrif
viral
load
measur
lung
day
postchalleng
figur
followingup
group
anim
receiv
vaccin
surviv
challeng
demonstr
rel
stabl
bodi
weight
figur
b
c
contrast
neg
control
anim
began
lose
weight
significantli
start
dpi
succumb
merscovma
infect
dpi
figur
b
c
sacrific
group
dpi
immun
anim
detect
viral
load
control
anim
averag
high
pfu
viru
lung
figur
togeth
result
indic
singl
intranas
immun
significantli
reduc
viral
replic
provid
complet
protect
lethal
merscovma
challeng
evalu
antibodi
contribut
observ
protect
transfer
immun
sera
either
balbc
mice
immun
nonimmun
mice
illustr
figur
n
neutral
titr
mouseadapt
merscovma
higher
immun
balbc
mice
figur
b
f
perhap
due
intrins
differ
two
anim
speci
effect
knockin
total
immun
sera
everi
immun
mous
wpi
transfer
individu
mice
intraperiton
ip
inject
one
day
challeng
lethal
dose
pfu
merscovma
sixteen
anim
receiv
either
balbc
immun
sera
monitor
daili
surviv
bodi
weight
chang
throughout
followup
rest
sacrif
viral
load
measur
lung
day
postchalleng
figur
consist
neutral
activ
immun
sera
balbc
mice
provid
protect
mice
result
mice
surviv
figur
c
g
signific
declin
bodi
weight
anim
receiv
immun
sera
balbc
mice
figur
howev
anim
receiv
mous
immun
sera
lost
approxim
bodi
weight
first
day
infect
gradual
recov
ensur
period
figur
h
control
mice
receiv
sera
sampl
empti
vector
immunizedanim
lost
weight
succumb
merscovma
infect
dpi
figur
sacrific
group
dpi
mice
passiv
receiv
immun
sera
immun
mice
significantli
lower
viru
titr
lung
empti
vector
immun
mice
sera
figur
e
togeth
find
confirm
antibodi
respons
induc
play
semin
role
protect
mice
lethal
challeng
merscovma
character
antibodi
respons
induc
isol
total
monoclon
antibodi
mab
antigenspecif
singl
splenocyt
immun
balbc
mice
use
merss
trimer
bait
antibodi
rather
diverg
vh
vl
gene
famili
figur
distribut
wide
without
appar
cluster
phylogenet
tree
figur
b
heavi
light
variabl
region
share
high
degre
similar
germlin
sequenc
studi
function
isol
antibodi
construct
fulllength
antibodi
backbon
mous
antibodi
produc
hek
cell
purifi
quantifi
bind
activ
recombin
trimer
rbd
protein
merscov
measur
elisa
shown
figur
c
antibodi
reactiv
merss
trimer
significantli
differ
activ
eight
clone
demonstr
exceedingli
high
bind
activ
activ
remaind
rel
low
among
eight
clone
seven
reactiv
protein
four
rbd
figur
c
control
mab
demonstr
expect
specif
previous
report
us
howev
four
antibodi
reactiv
rbd
demonstr
potent
broad
neutral
activ
wild
type
panel
major
mutant
pseudovirus
deriv
natur
occur
merscov
spike
sequenc
figur
potent
broad
neutral
activ
found
wild
type
mutant
strain
mean
respect
hand
show
modest
neutral
activ
mean
respect
fail
neutral
strain
bear
either
mutat
map
epitop
four
mab
conduct
competit
experi
antibodi
known
epitop
specif
publish
earlier
four
neutral
mab
compet
variabl
degre
fail
compet
figur
e
suggest
approach
rbd
manner
similar
also
conduct
sera
absorpt
experi
rbd
compar
neutral
activ
afterward
adsorpt
rbd
immun
sera
wpi
lost
wpi
lost
neutral
abil
merscov
pseudoviru
control
group
sera
adsorb
protein
show
chang
neutral
abil
fig
togeth
find
demonstr
observ
protect
confer
sera
immun
anim
larg
attribut
antibodi
target
rbd
highlight
critic
role
rbddirect
antibodi
respons
protect
merscov
continu
infect
human
caus
morbid
mortal
sign
abat
one
contribut
factor
high
preval
merscov
infect
among
dromedari
believ
major
reservoir
viru
immedi
sourc
human
infect
persist
merscov
anim
pose
sever
longterm
threat
global
health
highlight
urgent
need
prophylact
therapeut
intervent
studi
construct
recombin
rare
serotyp
chimpanze
adenoviru
express
fulllength
merscov
protein
potenti
vaccin
candid
merscov
infect
show
singl
intranas
immun
induc
robust
sustain
neutral
antibodi
cell
respons
balbc
mice
induc
immun
abl
provid
complet
protect
lethal
challeng
merscovma
mous
model
furthermor
passiv
transfer
immun
sera
mice
also
provid
substanti
surviv
advantag
lethal
merscovma
challeng
sera
absorpt
analysi
isol
monoclon
antibodi
immun
mice
demonstr
observ
potent
broad
neutral
activ
attribut
antibodi
target
rbd
protein
result
show
induc
protect
immun
respons
mice
repres
promis
candid
develop
merscov
infect
dromedari
human
two
uniqu
aspect
studi
highlight
first
relat
vector
prefer
profil
low
preexist
immun
overal
safeti
anim
human
clearli
advantag
mani
human
adenovir
vector
wide
use
vaccin
develop
human
adenoviru
compar
seropreval
human
seroposit
recent
engin
vaccin
candid
wide
rang
pathogen
hepat
c
viru
influenza
viru
ebola
viru
rsv
promis
preclin
result
brought
closer
clinic
applic
serotyp
chimpanze
adenovirusbas
vaccin
demonstr
similar
favour
profil
low
preexist
immun
advanc
clinic
studi
notabl
vaccin
express
fulllength
merscov
protein
alreadi
enter
phase
human
trial
metrap
vaccin
plasmodium
falciparum
prove
safe
highli
immunogen
human
encod
ebola
zair
glycoprotein
safe
induc
neutral
antibodi
cell
respons
ebola
viru
human
furthermor
encod
rsv
protein
f
n
encod
hepat
c
viru
protein
elicit
strong
immun
respons
clinic
trial
particip
result
demonstr
chimpanze
adenovir
vector
impress
safeti
toler
immunogen
profil
human
highlight
promis
vaccin
develop
second
uniqu
aspect
studi
except
protect
immunogen
mice
result
show
singl
intranas
immun
induc
robust
sustain
system
mucos
immun
respons
balbc
mice
immun
mous
model
provid
complet
protect
lethal
challeng
merscovma
initi
immun
high
persist
level
antibodi
great
contrast
induc
candid
vaccin
immunogen
shortliv
multipl
round
immun
requir
induc
detect
level
neutral
antibodi
confer
protect
viral
challeng
although
exact
mechan
behind
longlast
sustain
immun
respons
current
unknown
possibl
broad
tropism
host
cell
membraneanchor
instead
solubl
spike
protein
express
recombin
play
critic
role
importantli
intranas
immun
appear
superior
intramuscular
immun
induc
mucos
immun
respons
although
underli
mechan
remain
unclear
particularli
relev
merscov
infect
viral
transmiss
occur
larg
respiratori
tract
furthermor
eas
intranas
immun
also
offer
practic
conveni
method
requir
multipl
prime
boost
inject
therebi
improv
popul
coverag
previou
studi
util
chimpanze
adenovirus
intramuscular
immun
appear
elicit
better
immun
responsesprotect
intranas
inocul
differ
may
caus
differ
serotyp
adenoviru
vector
actual
antigen
anim
model
use
neutral
antibodi
cell
respons
appear
play
import
synergist
role
protect
immun
neutral
antibodi
like
directli
inhibit
merscov
entri
andor
function
fc
receptor
mediat
function
antibodydepend
cellular
cytotox
adcc
larg
natur
killer
nk
cell
antibodydepend
phagocytosi
adpc
larg
neutrophil
cell
hand
would
expect
recogn
kill
merscov
infect
cell
recognit
mhci
present
peptid
test
current
studi
howev
passiv
transfer
immun
sera
mice
provid
substanti
protect
lethal
merscovma
challeng
thu
reason
hypothes
antibodi
mediat
effector
function
may
suffici
protect
particular
analysi
sera
absorpt
isol
monoclon
antibodi
immun
mice
indic
protect
respons
larg
attribut
antibodi
target
rbd
protein
coincid
previou
report
vaccin
candid
base
rbd
alon
induc
protect
antibodi
respons
merscov
infect
also
consist
earlier
find
neutral
monoclon
antibodi
target
rbd
suffici
provid
protect
collect
result
demonstr
except
capac
induc
protect
immun
respons
mice
notabl
eas
deliveri
repres
promis
candid
develop
merscov
infect
dromedari
human
